SCHEMBL192020

SCHEMBL192020

COC(=O)c1cccc(Oc2ccnc(Cl)c2)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.64
NR1H2 P55055 2/20 0.52
NR1H3 Q13133 1/20 0.52
PPARG P37231 1/20 0.50
KDM4E B2RXH2 1/20 0.48
KDM6B O15054 1/20 0.48
KDM5C P41229 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
KDM2A Q9Y2K7 1/20 0.48
KDM3A Q9Y4C1 1/20 0.48
KDR P35968 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MET P08581 1/20 0.46
ALK Q9UM73 1/20 0.46
GRM5 P41594 3/20 0.46
CYSLTR1 Q9Y271 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436534 0.83 L3MBTL1 (0.65) L3MBTL1MEN1KMT2ATP53SMN1; SMN2
SCHEMBL6243390 0.82 L3MBTL1 (0.58) L3MBTL1NR1H2NR1H3KDM4EMEN1
SCHEMBL390165 0.80 KDM4E (0.60) L3MBTL1KDM4EKDM6BKDM5CKDM4C
SCHEMBL2671292 0.80 NOTUM (0.46) L3MBTL1NR1H2NR1H3KDM4EKDM6B
SCHEMBL5423254 0.80 KDR (0.56) L3MBTL1KDR
SCHEMBL6798334 0.80 MEN1 (0.72) L3MBTL1KDM4EKDM6BKDM5CKDM4C
SCHEMBL1460564 0.79 TTR (0.44) L3MBTL1KDM4EKDM6BKDM5CKDM4C
SCHEMBL521860 0.79 AKR1C3 (0.68) L3MBTL1MEN1KMT2ATP53SMN1; SMN2
SCHEMBL23582263 0.78 L3MBTL1 (1.00) L3MBTL1NR1H2NR1H3PPARGKDM4E
SCHEMBL31357611 0.78 L3MBTL1 (1.00) L3MBTL1NR1H2NR1H3PPARGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 L3MBTL1 525/4885NR1H2 611/4885NR1H3 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.